Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This study is to characterize the safety and tolerability of an investigational drug called
DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose
part (Part B) in well-controlled celiac disease patients.